Navigation Links
Research uncovers key difference between our bodies' fight against viruses and bacteria
Date:1/12/2014

Scientists at The University of Nottingham have discovered a key difference in the biological mechanisms by which the immune system responds to viral and bacterial pathogens.

The study, published in the journal Nature Immunology and led by Professor Uwe Vinkemeier in the University's School of Life Sciences, centred on STAT1, a protein that can bind DNA and hence plays a vital role in regulating genes in the body.

STAT-1 responds to interferon signals, hormone-like molecules which control communication between cells to trigger defensive action by the body's immune system when pathogens such as bacteria, viruses, or parasites are detected. These powerful defensive actions are also part of the body's ability to control the growth of malignant tumours that can ultimately achieve their complete elimination.

It was previously thought that all interferons used single STAT1-containing units rather than STAT1 chains to regulate the activity of genes. However, using mice bred specially to express a mutated form of STAT1 which is limited to forming single STAT1 units, the Nottingham team has demonstrated that this abolishes the function of some interferons while leaving others largely unaffected.

They found that when the assembly of STAT1 chains was inhibited, type I interferons responsible for protecting against viruses such as vesicular stomatitis virus were unaffected, whereas type II interferons, which protect against bacterial infections such as listeria, no longer functioned effectively.

Professor Vinkemeier said: "The core of these findings is that we are revising a central aspect of what we thought we knew about how these proteins worked. The molecular mechanisms underlying type I and type II interferon functioning are actually more distinct than we previously imagined. This in turn offers new options for rational pharmacological intervention."

For example, type I interferons, involved in the anti-viral response also play a role in stopping cells from growing and replicating and therefore inhibiting the spread of the virus throughout the body. These interferons are already in clinical use against Hepatitis virus and several cancers and in the treatment of auto-immune diseases like multiple sclerosis. Type-II interferon, in contrast, has been shown to be detrimental in some of these conditions, namely multiple sclerosis and melanoma, an aggressive type of skin cancer.

"In situations like these our finding offers a new target for making current treatments more effective. There is good reason to assume that an inhibitor of STAT1 chain formation could potentially block detrimental type-II interferon responses while keeping type I activities, including anti-viral protection, intact. This would avoid an important shortcoming of current STAT1 inhibitors."


'/>"/>

Contact: Emma Thorne
emma.thorne@nottingham.ac.uk
44-011-595-15793
University of Nottingham
Source:Eurekalert

Related biology news :

1. KIT researchers develop artificial bone marrow
2. Researchers pursuing arthritis protein
3. LSUHSC research reveals structure of master regulator and new drug target for autism, cervical cancer
4. Researchers discover a tumor suppressor gene in a very aggressive lung cancer
5. Researchers unveil rich world of fish biofluorescence
6. Stem cell research identifies new gene targets in patients with Alzheimers disease
7. 2014 ASM Biodefense and Emerging Diseases Research Meeting
8. Researchers propose alternative way to allocate science funding
9. New research: Effects of eating half an avocado with lunch on satiety & desire to eat between meals
10. New research study: The snowball effect of overfishing
11. A CNIO research team discovers new regulators of the most prevalent liver disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2016)... HAMBURG, Germany , March 9, 2016 ... African country,s government identified that more than 23,000 public ... name or had been receiving their salary unlawfully.    ... West African country,s government identified that more than 23,000 ... recorded name or had been receiving their salary unlawfully. ...
(Date:3/8/2016)... RALEIGH, N.C. , March 8, 2016 /PRNewswire/ ... biometric sensor technology, today announced it has secured ... led by GII Tech, a new venture fund ... LLC, with additional participation from existing investors TDF ... use the funds to continue its triple-digit growth ...
(Date:3/3/2016)... March 3, 2016  2016FLEX, organized by FlexTech, ... highlighting advancements in flexible, hybrid and printed electronics. ... attendance - have gathered for short courses, technical ... of electronics. The Flex Conference celebrates its 15 ... companies, R&D organizations, and universities contributing to the ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... Lajollacooks4u has ... and has consistently been rated one of its top attractions. Fortune 500 companies, ... to participate in a unique and intimate team-building experience. , Each event kicks off ...
(Date:5/25/2016)... ... May 25, 2016 , ... The ... fracture-specific plating options designed to address fractures of the distal tibia and fibula. ... The Acumed Ankle Plating System 3 is composed of seven plate families that ...
(Date:5/25/2016)... Md. (PRWEB) , ... May 25, 2016 , ... ... request for information (RFI) issued by the Office of the National Coordinator for ... patient experience, and determines if clinically relevant data were available when and where ...
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority on the ... Charles W. Stellar has been named by the WEDI Board of Directors as WEDI’s ... an executive leader with more than 35 years of experience in healthcare, association management ...
Breaking Biology Technology: